HemaCare Committed to Cell Therapy Research Through Strategic Agreements
Provides Biologic Source Material for Complex Immunotherapies Research, Product Development
(Los Angeles, CA – October 19, 2015) HemaCare Corporation (OTCBB: HEMA), a leader in cell and tissue collection, processing and cell therapy solutions, has expanded its growing cell therapy client portfolio through several supply agreements with Cellectis, Dendreon, and Sotio. Under the agreements, HemaCare provides process development support and supplies high-quality cGMP and research-grade biological material for use in cell therapy research and development of commercially available products, including Provenge®.
According to Pete van der Wal, HemaCare’s Chief Executive Officer, these agreements are a testament to the company’s growing footprint in the cell therapy space – HemaCare’s fastest growing and most profitable segment. In 2014, HemaCare tripled revenues from custom cell collection services for clinical research or therapeutic use over the prior year. Thus far in 2015, HemaCare’s market penetration continues to accelerate.
“Our leadership in cell and tissue collection has placed us in the ideal position to support the unique needs and requirements of the scientific community in the rapidly emerging cell therapy space,” van der Wal said. “Our expertise in apheresis collection that supports cell manufacturing process development and clinical trials has made us the preferred partner to support even the most complex research projects.”
Obtaining high-quality biological material is a critical determinant of clinical trial outcomes and product quality for the therapeutic use of cell therapies. Leveraging its 37-year track record in apheresis, HemaCare has optimized cell collection procedures within its FDA-registered, cGMP- and AABB-compliant donor collection center. This enables the company to deliver a higher degree of reproducibility in cell collection to any research project, process development, or manufacturing effort based on cGMP principles, and in accordance with IRB-approved protocols.
Since 1978, HemaCare Bioresearch Products & Services has been the trusted research partner of choice from concept to commercialization. Built on a 37-year history in apheresis collection, HemaCare is a leader in Cell and Tissue Collection, Processing and Cell Therapy, providing the high-quality biological material needed to ensure quality research outcomes that meet the unique needs of the scientific community. For more information please visit www.hemacare.com.